The complete and partial recanalization of PVT was observed in 41 patients. ResultsĪ total of 94 patients were included, 52 patients (55%) received rivaroxaban and 42 (45%) with dabigatran. The Cox proportional hazards model was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). The log-rank test was used to compare Kaplan–Meier distributions of time-to-event outcomes. Outcomes included recanalization (complete, partial, and persistent occlusion), liver function, bleedings, and survival. The severity of liver cirrhosis was assessed using Child–Pugh score and Model for End-Stage Liver Disease (MELD) score. The diagnosis of acute PVT was confirmed by imaging examinations. The demographic, clinical, and imaging data of patients were collected. The patients received oral anticoagulation with rivaroxaban or dabigatran. This retrospective study included all consecutive cirrhotic patients with acute portal vein thrombosis in our institute from January 2020 to December 2021. The difference of the efficacy and safety between rivaroxaban and dabigatran remains unclear in the treatment of cirrhotic patients with acute portal vein thrombosis (PVT). New oral anticoagulants (NOACs) have been becoming prevalent in recent years and are increasingly used in the treatment of port vein thrombosis.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |